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a b s t r a c t
Ferroptosis is a recently discovered form of iron-dependent regulated cell death (RCD) that occurs via peroxidation of phospholipids containing polyunsaturated fatty acid (PUFA) moieties. Activating this form of
cell death is an emerging strategy in cancer treatment. Because multiple pathways and molecular species
contribute to the ferroptotic process, predicting which tumors will be sensitive to ferroptosis is a challenge. We thus develop a mathematical model of several critical pathways to ferroptosis in order to perform a systems-level analysis of the process. We show that sensitivity to ferroptosis depends on the
activity of multiple upstream cascades, including PUFA incorporation into the phospholipid membrane,
and the balance between levels of pro-oxidant factors (reactive oxygen species, lipoxogynases) and antioxidant factors (GPX4). We perform a systems-level analysis of ferroptosis sensitivity as an outcome
of ﬁve input variables (ACSL4, SCD1, ferroportin, transferrin receptor, and p53) and organize the resulting
simulations into ‘high’ and ‘low’ ferroptosis sensitivity groups. We make a novel prediction corresponding
to the combinatorial requirements of ferroptosis sensitivity to SCD1 and ACSL4 activity. To validate our
prediction, we model the ferroptotic response of an ovarian cancer stem cell line following single- and
double-knockdown of SCD1 and ACSL4. We ﬁnd that the experimental outcomes are consistent with our
simulated predictions. This work suggests that a systems-level approach is beneﬁcial for understanding
the complex combined effects of ferroptotic input, and in predicting cancer susceptibility to ferroptosis.
© 2020 The Authors. Published by Elsevier Ltd.
This is an open access article under the CC BY-NC-ND license.
(http://creativecommons.org/licenses/by-nc-nd/4.0/)

1. Introduction
Ferroptosis is a recently discovered form of regulated cell
death (RCD) that is triggered by iron-dependent lipid peroxidation (Stockwell et al., 2017). Ferroptosis is a member of a
broader family of RCD pathways that also includes necroptosis,
parthanatos, pyroptosis, apoptosis, and others (Stockwell et al.,
2017; Vandenabeele et al., 2010; Conrad et al., 2016; Vanden
Berghe et al., 2014; Galluzzi et al., 2018). Critical features of RCD
processes include control by speciﬁc intrinsic cellular mechanisms,
resulting in susceptibility of RCD to pharmacologic and genetic
modulation. This distinguishes RCD from accidental death caused
by severe chemical or mechanical insults (Vandenabeele et al.,
2010; Conrad et al., 2016; Vanden Berghe et al., 2014). Different
∗
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types of RCD serve complementary roles during homeostatic,
developmental, and pathogenic processes. For example, apoptosis,
perhaps the best-studied mechanism of RCD, is programmed to occur in normal physiological contexts such as development (Galluzzi
et al., 2018). RCD can also serve as a form of intercellular communication: release of oxidized lipids resulting from a cell undergoing
ferroptosis may serve to promote ferroptosis and other forms of
cell death in nearby cells (Conrad et al., 2016). In addition, cellular
internal state can drive a cell to undergo one vs. another form of
RCD, as exempliﬁed by the inﬂuence of autophagy, the process of
regulated lysosomal degradation of cytoplasmic components, on
the cellular decision to undergo RCD (Loos and Engelbrecht, 2009;
Napoletano et al., 2019; Hou et al., 2016). Therefore, development
of a systems-level understanding of ferroptosis becomes critical
not only for understanding and predicting the process itself, but
also for developing more comprehensive models of cell survival
and death under a wide range of conditions.

https://doi.org/10.1016/j.jtbi.2020.110222
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Both intentional induction of ferroptosis and its prevention are
the focus of current drug development efforts. Thus, ferroptosis
inhibitors are being considered as agents for the treatment of
neurodegenerative disease (Angeli et al., 2017; Wu et al., 2018);
conversely, substantial effort is being directed at the discovery of
ferroptosis-inducing agents to treat cancer (Stockwell et al., 2017;
Shen et al., 2018). Further, recent work suggests that existing anticancer agents such as cisplatin and soraﬁnib trigger ferroptotic
pathways (Guo et al., 2018; Lachaier et al., 2014a; Lachaier et al.,
2014b). The ﬁnding that drug-tolerant “persister” cells are particularly vulnerable to ferroptosis inducers has further heightened
interest in ferroptosis as a potential mechanism for treating drug
resistant cancers. Ovarian cancer, a malignancy in which successful
treatment is frequently thwarted by the emergence of drug resistance (Agarwal and Kaye, 2003; Norouzi-Barough et al., 2018), may
be an ideal candidate for such an approach. Indeed, our laboratory
has shown that ovarian cancer cells are exquisitely sensitive to
ferroptosis inducers in vitro and in vivo (Basuli et al., 2017).
Sensitivity to ferroptosis is complex and depends on multiple
interacting molecular components. Here, we use mathematical
modeling to synthesize currently understood ferroptotic processes
into a dynamic, predictive model to better understand how
ferroptotic processes can be harnessed for anti-cancer therapy.
Such a model can be used to predict the cellular phenotype(s)
that are optimal for ferroptotic sensitivity, as well as the relative
contributions of molecular species and submodules in the network to the ferroptotic response. Indeed, mathematical models
of apoptosis have helped to answer a number of outstanding
biological questions with respect to this form of regulated cell
death (Schleich and Lavrik, 2013), as well as to develop optimized
protocols for oncotherapy (Panetta and Fister, 20 0 0; Konstorum et
al., 2017). Models that explore the inﬂuence of autophagy on the
cell decision process to undergo apoptosis (Tavassoly et al., 2015;
Liu, 2017), and the cell decision process to survive or undergo
apoptosis or necrotic cell death (Calzone et al., 2010), provide
examples of how integration of different models for cell death and
survival can be accomplished.
Kagan et al. (2017) recently developed a continuum model
for ferroptosis with a focus on biochemical cascades occurring
in the phosphatidylethanolamine (PE) class of phospholipids.
While that model provides an excellent synthesis of speciﬁc
processes involved in arachidonic acid metabolism, lipoxogynase
activity, and GPX4 regulation, it excludes contributions of iron,
lipid desaturases, and additional components of import to the
lipid peroxidation processes involved in ferroptosis. Agmon et al.
(2018) performed molecular dynamics simulations of membranes
with compositions relevant to ferroptotic sensitivity, and showed
how the biophysical properties of membranes are altered under
ferroptotic-competent lipid compositions.
We developed our model to answer systems-level questions
regarding ferroptosis sensitivity and its interdependence on the coordinated activities of several distinct molecular species that have
been identiﬁed as central to the ferroptotic signaling pathway, with
a focus on species that have been found important for the lipid
peroxidation processes critically involved in ferroptosis (Dixon and
Stockwell, 2014; Yang and Stockwell, 2016; Stockwell et al., 2017).
We use a multistate discrete modeling approach to emphasize
qualitative properties of signaling cascades relevant to ferroptosis.
The discrete modeling approach allows us to investigate the relative importance of different drivers of ferroptosis using a wider
range of data than would be available for a detailed kinetic model
of the system. Discrete models can provide a mechanistic, systemslevel, understanding of a process that can serve to better focus
future detailed kinetic modeling. Discrete models have been used
successfully to model a variety of important processes in cancer,
including cell cycle progression driven by PI3K (Sizek et al., 2019),

the topography of epithelial-mesenchymal transitions (Font-Clos et
al., 2018), and transcription factor networks in small cell lung cancer (Sizek et al., 2019; Font-Clos et al., 2018; Udyavar et al., 2017).
Using this model, we connect signaling modules related to
phosholipid precursor processing, phospholipid peroxidation, ROS
signaling and generation, and GPX4 activity, and demonstrate
how each contributes to ferroptosis sensitivity. We demonstrate
how the model can be used to make novel predictions about the
combined impact of multiple perturbations on the response to
ferroptosis, and provide a proof-of-principle experimental validation of these predictions. We provide source-code for the model
in (Konstorum, 2020).

2. Results
2.1. Model overview
Using the available literature, we developed a logic-based multistate model for the intracellular ferroptotic process, with a focus
on pro- and anti-oxidant actors in lipid peroxidation (Fig. 1). All
model components were chosen such that they were found to be
central components in pro-and anti-oxidant processes in ferroptosis, and each individually was identiﬁed to play a promotional or
inhibitory role in ferroptosis. The goal for model development was
to investigate how the activity of these actors modiﬁes ferroptotic
sensitivity in a systems analysis. We provide an overview of how
model components (underlined) were chosen, and refer the reader
to Section 4 (Methods) for a more detailed description of individual component biology, evidence of importance for ferroptosis,
and mechanism of model incorporation.
Ferroptosis is characterized by iron-dependent lipid peroxidation that occurs in the presence of agents, such as erastin or RSL3,
that inhibit counteractive antioxidant processes (Dixon et al., 2012).
An antioxidant process found to be critical in protection from ferroptosis is mediated by the lipid peroxidase GPX4 (Yang et al.,
2014). In order for ferroptosis to proceed, phospholipid molecules
containing polyunsaturated fatty acids (LH-P) are generated from
acetylated polyunsaturated fatty acids (PUFA-CoA) in a process
that depends on the presence of the LPCAT3 enzyme (and relative
absence of monounsaturated fatty acids, MUFAs, which can be produced by desaturation by SCD1 of saturated fatty acids (SFAs)). The
PUFA-CoA moieties are produced from membrane polyunsaturated
fatty acids (PUFAs) such as Arachidonic Acid (AA) by acyl-CoA
synthetases such as ACSL4, an enzyme whose activity has been
found to be critical for ferroptosis sensitivity (Doll et al., 2017;
Dixon et al., 2015). The LH-P are oxidized to lipid hydroperoxides
(LOOH) and eventually to lipid radicals (LO• ) - which contribute
to the initiation of ferroptosis - by reactive oxygen species (ROSs)
and/or lipid peroxidating enzymes such as ALOX15, which act as a
trigger for cell death (Feng and Stockwell, 2018). Presence of GPX4
can mitigate this process since it can reduce LOOH to LOH, thereby
preventing its further oxidation. Iron, which promotes the formation of ROS through Fenton chemistry, is also required for ferroptosis (Dixon et al., 2012). Cellular levels of iron are dependent on
several proteins, notably TFR1, an iron importer that is generally
upregulated in cancer, and ferroportin (Fptn), an iron eﬄux pump
that is downregulated in cancer (Torti and Torti, 2011; Torti and
Torti, 2013; Torti et al., 2018). Additionally, p53 can act in two ways
to promote ferroptosis: by increasing ALOX15 (Ou et al., 2016),
and inhibiting SLC7A11, a component of the cystine/glutamate
antiporter system xc − (cystine is a necessary precursor for GPX4
production).
The model is informed by results from multiple cell types
and over 25 publications (see Methods for full model details).
Each molecular species can take on a value of ‘low’ (0), ‘medium’
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Fig. 1. Diagrammatic overview of the multistate model for ferroptosis. Input parameters are model elements that do not change during the course of the simulation (blue
outline; dashed line beneath), model variables on the other hand will change concentrations until reaching a steady state (blue outline). Molecular species that are implicitly
included in the model but not simulated are also shown (black outline) as well as ferroptosis inducers (green outline). AA: arachidonic acid, LH-P: phospholipid conjugated
•
to polyunsaturated fatty acid, LIP: labile iron pool, LOOH: lipid hydroperoxide, LO : peroxide radical, LOH: redox-inert alcohol, MUFA: monounsaturated fatty acids, PL:
phospholipid, PUFA-CoA: acetylated polyunsaturated fatty acids, ROS: reactive oxygen species, system xc − : cystine/glutamate transporter, SFA: saturated fatty acids.

(1), or ‘high’ (2) activity/expression. Such a coarse-grained model
can be used to understand qualitative characteristics of a system
without detailed knowledge of biochemical rate parameters. Such
models, which can specify functions using logical rule gates or
transition tables, have been used successfully as described in the
Introduction, as well in further studies such as to obtain novel
biological understanding in cancer cell metabolism (Chifman et al.,
2017), T cell receptor signaling (Saez-Rodriguez et al., 2007), innate
immune response (Dimitrova et al., 2018), and a variety of other
biochemical networks (Morris et al., 2010).
Initial conditions for the model are set as described in the
Supplementary Information, Section S1 and Table S1. We note that
simulation steady states do not depend on the initial conditions.
The settings for the input parameters SCD, TFRC, Fptn, p53, and
ACSL4 are all set to medium except for ACSL4, which is set to
‘high’. The latter condition is set since our simulations showed
that a high ACSL4 is required to achieve a maximal ferroptotic
response under any conditions of the other input variables. Other
levels of ACSL4 and the other input variables are explored in
Section 2.3.2. Further details on initial conditions for the model

variables and input parameters are found in the Supplementary
Information, Section S1. Full source-code for the model can be
found in (Konstorum, 2020)
2.2. Response to ferroptosis inducers
We consider the steady state reached by the cells in our
simulation with and without ferroptosis stimulation by erastin
or RSL3, two small molecules speciﬁcally designed to induce
ferroptosis that are widely used in the literature (Stockwell et al.,
2017; Dixon et al., 2012) (Fig. 2). We observe that without ferroptosis induction, the cell has a high level of PUFA precursors
for incorporation into phospholipids (PUFA-CoA), and a moderate
incorporation of these moieties (LH-P), as well as moderate levels
of hydroperoxides (LOOH). MUFA and LPCAT3 levels are moderate,
as well as ROS. GPX4, SLC7A11, and ALOX15 are high. Importantly,
although there are moderate levels of LOOH, there are low levels
of peroxide radicals (LO• ), which can lead to ferroptosis. One can
consider such a cell primed for ferroptosis due to the presence of
LOOH and oxidizers ALOX15 and ROS. The high levels of GPX4 pre-
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Fig. 2. Addition of erastin or RSL3 in the baseline model stimulates a ferroptotic response. Steady state values of baseline model variables are shown (a) without and (b)
with addition of the ferroptosis-inducers erastin or RSL3. Note that only SLC7A11 responds differently to erastin (no change) vs. RSL3 (lowered). Variables in gray (‘Input’)
are external, and thus are set at time t = 0 and stay constant throughout the course of the simulations. The remainder of the variables are classiﬁed by types of molecular
species or mode of action.

vent the cell from undergoing ferroptosis. Upon addition of erastin
or RSL3, GPX4 levels are reduced, and we observe the appearance
of moderate levels of ferroptosis via LO• (Fig. 2b). Note that erastin
acts by inhibiting SLC7A11, which decreases availability of cysteine
substrate for production of GSH, a co-factor required for GPX4
activity, whereas RSL3 inhibits GPX4 directly, hence SLC7A11 levels
are still high in the RSL3+ cell. Thus the model accurately captures
basic features of the ferroptotic response, an important ﬁrst step
towards its use for elucidating novel systems-level requirements
for ferroptosis.
2.3. In silico system perturbation
2.3.1. Single perturbation: ACSL4
To test the model, we ﬁrst performed a simple in silico perturbation that mimics an experiment with a known outcome. ACSL4
inhibition prevents ferroptosis (Doll et al., 2017). We use RSL3 as
our ferroptosis-initiator in the model, following Doll et al. (2017).
We observe that, compared to control baseline (Fig. 2a), in the
ACSL4 knock-out model (Fig. 3a) there is low incorporation of PUFAs into phospholipids, and thus less peroxidated phospholipids.
Even with the addition of the GPX4 inhibitor RSL3 (Fig. 3b), we
do not see an increase in peroxidated phospholipids because their
precursors are not available – thus reproducing the ﬁndings of
Doll et al. (2017).
2.3.2. Systems biology of ferroptosis
To more comprehensively understand how combinations of
perturbations of system variables will impact ferroptotic response,
we simulated the effect of all combinations of the input variables
(35 = 243) on system behavior without or with addition of a ferroptotic agent (Fig. 4). We sort the perturbations by (1) decreasing
LO• value in the erastin+ treatment group and (2) for each LO•
value-subgroup in the erastin treatment group, increasing LO•
value in the control treatment group. In this way, the patterns of
the input variables that lead to the maximal ferroptotic response
in each subgroup are easily identiﬁable. A comprehensive set of
simulations is necessary to tease out the inter-related impact of
the input variables on ferroptosis sensitivity, since the value of
any one input variable is usually not, alone, predictive of ferrop-

totic response when all other input variables are allowed to vary
(Supplementary Information, Section S2).
We analyze the output of the respective high and low ferroptotic response subgroups, and include an analysis of the
intermediate ferroptotic response in the Supplementary Information (Section S3). We conclude this subsection with a summary of
the results in the form of a rule-based ‘algorithm’ for the cell that
allows for a signature-based analysis of the input variables with
respect to outcome in ferroptosis sensitivity.
2.3.2.1. High ferroptotic response. The high ferroptotic response
corresponds to ~6.17% of the input conditions, making it the most
rare outcome. We note that for the cell to achieve a high ferroptotic response with erastin treatment, ACSL4 must be at its highest
value, and SCD1 at its lowest value (Fig. 5). This combination
yields maximal PUFA levels (due to high ACSL4) and maximal LH
levels (due high ACSL4 and low SCD1/MUFA). While we observe
high PUFA and LH in a small subset of low-ferroptotic response
signatures (Fig. 6), only the high ferroptotic response signatures
also have high LOOH, priming them for generating LO• in the
absence of GPX4. The ﬁrst peroxidation step is achieved by ROSs
and/or ALOX15, and we see that ALOX15 and ROS levels are never
low in the high ferroptotic signature cells. Additionally, for the
cells to be sensitive to ferroptotic agents, p53 must be either
at low or medium levels, otherwise SLC7A11, and hence GPX4
activity, is dampened, allowing for high LO• to be generated even
in the control-treated cells. This may explain why results of p53
inhibition in the literature are varied: when p53 is lowered below
maximal level, other factors contribute and may even predominate
in determining ferroptosis sensitivity. This may be an interesting
direction to pursue with respect to developing a more in-depth,
kinetic model focusing on p53 in ferroptosis in order to further
understand how this interplay impacts ferroptosis sensitivity.
2.3.2.2. Non-responsive ferroptosis cases. We note that the no
ferroptosis/non-responsive cases, which make up ~71.61% of the
responses (Fig. 6), include a wide range of input variable values,
but they all share one feature: there is no LOOH present in all
the cases, whereas LOOH is at intermediate or high levels in the
remainder of the simulations (Fig. 4). As can be observed in Fig. 1,
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Fig. 3. Effect of ACSL4 knock-out on model behavior (a) without and (b) with addition of RSL3.

Fig. 4. Ferroptosis model output with all combinations of input conditions, sorted by ferroptotic response.
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Fig. 5. Ferroptosis model output with all combinations of input conditions, sorted by ferroptotic response, displaying high ferroptosis after erastin treatment.

LOOH provides the initial substrate for lipid peroxidation (another
way to consider this is that LOOH is upstream to LO• , the peroxide
radical that leads to ferroptosis). As can be observed from the
simulations, and intuited from the diagram in Fig. 1, LOOH is thus
necessary (but not suﬃcient) for cellular ferroptotic sensitivity.
With no substrate for pro- or anti-oxidant activity, ferroptosis
cannot be induced. As evidenced here, lack of LOOH can be
induced by a large number of combinations of input conditions.
Nevertheless, we do see certain conditions emerge that result in
non-responsiveness: ACSL4, which catalyzes conversion of AA to
PUFA-CoA, is necessary (but not suﬃcient) for production of LOOH.
Therefore, all conditions with no ACSL4, regardless of the other input variables, are identiﬁed as non-responsive. Indeed, experiments
in Section 2.4 bear out this observation for a subset of conditions.
2.3.2.3. A rule-based ‘algorithm’ for cellular sensitivity to ferroptosis.
We can summarize the results of the systems analysis using a rulebased approach for the input variable levels (Fig. 7). These rules
can be deduced from Figs. 4–6, Methods (Section 4.2), and Figure
S2. This approach allows for an analysis akin to a ‘gene-signature’
approach to determine ferroptosis sensitivity, as well as succinctly
summarizes the various dependencies that the cell requires to
initiate ferroptosis either with or without addition of a ferroptotic
agent. For example, provided levels of input variables are available,
one can predict whether a cell with high levels of PUFA-containing
phospholipids (LOOH) will undergo spontaneous ferroptosis by
observing the activity of p53 in the cell. Alternatively, a cell with

a combination of input variables that results in moderate LOOH,
but not high ROS levels, will not undergo spontaneous ferroptosis
even under high levels of p53. Much of the intuition surrounding
the rules in Fig. 7 can be found in the discussion contained within
Sections 2.3.2.1 and 2.3.2.2. We consider this cellular ‘algorithm’
for ferroptosis sensitivity as a ﬁrst approach towards considering
what gene signatures may emerge as predictive for ferroptosis
sensitivity in a translational setting.
2.4. Predicting and testing the response of an ovarian cancer stem
cell line to ferroptotic agents
We use our model to predict and then experimentally test
the response of an ovarian cancer stem cell line to ferroptotic
agents. FT-t cells are a model of high-grade serous ovarian cancer
(HGSOC) stem cells that were derived from primary culture of
fallopian tube stem cells (considered to be one of the major cells
of origin for HGSOC (Kim et al., 2018)) via immortalization and
transformation with h-TERT, SV40 large T antigen, and c-MYC
(Yamamoto et al., 2016). When implanted in mice, FT-t cells
form tumors that accurately mimic genetic features of HGSOC
(Basuli et al., 2017; Yamamoto et al., 2016), rendering it a useful
test case for how the model might predict the response of HGSOC
to ferroptosis inducers. In particular, this cell line has low p53
(due to inactivation by SV40), high TFRC, and low ferroportin,
thereby displaying a high iron retention phenotype (Basuli et al.,
2017). We can therefore use our system to model this cell line by
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Fig. 6. Ferroptosis model output with all combinations of input conditions, sorted by ferroptotic response, displaying low ferroptosis after erastin treatment.

setting the input variables (p53, TFRC, ferroportin) = (low, high,
low). We can then analyze the response of the simulated cell line
to ferroptosis inducers as a function of the remaining two input
variables ACSL4 and SCD1 (Fig. 8).
We observe that due to high TFRC and low Fptn, we have
maximal LIP and ROS levels (while ROS can also be increased by
feedback from LO• in lower iron conditions, an iron retention
phenotype leads to maximal ROS in our model). Due to the low
p53, we have intermediate ALOX15: while ALOX15 is boosted
by p53 activity, lack of p53 does not completely abrogate its
expression and function. Even though p53 activity is low, due to
the high iron, these cells are primed to undergo ferroptosis in the
right conditions.
If SCD1 activity is low, there are few MUFAs to inhibit LPCAT3,
and directly inhibit PUFA incorporation into phospholipids. Therefore, LH-P levels are completely determined by ACSL4 activity, and
LOOH is proportional to LH-P due to the high ROS. Thus, these cells
will undergo ferroptosis upon inhibition of GPX4 activity if enough
ACSL4 is present. If SCD1 activity is intermediate, there is partial
inhibition of LPCAT3 and PUFA incorporation into phospholipids,
evidenced by lower LH-P even at high ACSL4. Cells still respond to
ferroptotic agents in the presence of ACSL4, but cannot maximize
a ferroptotic response. Under conditions of high SCD1 activity,
there is low LH-P due to MUFA-mediated inhibition of PUFA
incorporation into phospholipids. Therefore, there is no substrate
for ferroptosis to be initiated upon addition of ferroptotic agent.
Overall, the model predicts that in the genetic background of
FT-t cells, SCD1 knock-out will increase sensitivity to ferroptosis,

but a double-knockout of ACSL4 and SCD1 will prevent this SCD1knockout induced increase (Fig. 8). To note, such a prediction is
not possible using a static model, due to the complexity of interactions between the input parameters and model variables. For
example, one can observe input parameter combinations where a
low SCD1 and high ACSL4 background will not increase ferroptosis
sensitivity (Fig. 6).
To test these predictions experimentally, we ﬁrst ascertained
the level of ACSL4 and SCD1 in FT-t cells in comparison to FT
(primary fallopian tube stem cells) and FT-i (FT cells that have
been immortalized but not transformed). We observed that both
ACSL4 and SCD1 mRNA were elevated in FT-t in comparison to FT
(Supplementary Figure 3), indicating that both of these genes are
highly expressed in the model ovarian cancer stem cell line. Next,
we knocked-down SCD1, ACSL4, or both genes using siRNA pools
and assayed cell viability following treatment with the ferroptosis
inducer RSL3. A knock down of SCD1 and/or ACSL4 corresponds to
setting the respective input parameter to ‘low’ in the model with
other parameters maintained as discussed previously (Fig. 8).
The results of this experiment are shown in Fig. 9. As seen
in Fig. 9a, knockdown of SCD1 was successful, resulting in an
approximately 80% decrease in levels of SCD1 mRNA. Similarly,
knockdown of ACSL4 resulted in an 80% decrease in levels of ACSL4
when compared to a non-targeting control (Fig. 9b). Somewhat
unexpectedly, knockdown of SCD1 slightly elevated ACSL4 mRNA
(Fig. 9b) and conversely, knockdown of ACSL4 elevated levels of
SCD1 mRNA (Fig. 9a) above that of controls. We currently have no
explanation for this apparent crosstalk, which to our knowledge
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Fig. 7. A cellular algorithm for ferroptosis sensitivity. Provided known values of input variables (in blue), one can follow the algorithm to understand how a cell will ‘decide’
whether to undergo spontaneous or drug-induced ferroptosis. This algorithm provides a rule-based summary of the model steady state outcomes.

has not been previously reported and merits further investigation.
Nevertheless, as expected, levels of both mRNAs remained low
when both were knocked down together (Fig. 9a,b).
The successful knockdown of SCD1 and ACSL4 enabled us to
test the effect of both single and double knockdowns on sensitivity to ferroptosis. As shown in Fig. 9c, control cells were sensitive
to the ferroptosis inducer RSL3, exhibiting an approximately 20%
decrease in viability. Sensitivity was dramatically enhanced (to approximately 80%) when SCD1 was knocked down, consistent with
model predictions and with a role of SCD1 as a cytoprotective protein (Tesfay et al., 2019). However, as predicted by the model, this
enhanced cytotoxicity was blocked in cells in which ACSL4 was simultaneously reduced (Fig. 9c, compare yellow bar to black bar in
the central panel). Concurrent treatment of cells with the ferroptosis inducer RSL3 and the ferroptosis inhibitor ferrostatin blocked
cell death in all cases (Fig. 9c), demonstrating that effects on cell
viability were attributable to the process of ferroptosis and not to
another cell death mechanism. Further, staining with trypan blue,
which directly stains dead cells (as opposed to the calcein staining shown in Fig. 9c, which stains living cells, with death being
inferred from a reduction in viability) conﬁrmed that knockdown
of SCD1 only increases cell death in a genetic background in which
ACSL4 has not been simultaneously reduced (Fig. 9d). Collectively,
these data demonstrate that our systems-level model can accurately predict sensitivity to ferroptosis induction as an outcome
of the activity of multiple components of the ferroptotic induction
cascade.
3. Discussion
Ferroptosis is a recently-described mode of cell death that is
distinct from other known cell death pathways. The discovery
of ferroptosis has engendered wide-spread interest in the development of anti-cancer drugs that induce this mechanism of
cell death (Stockwell et al., 2017). Although such drugs currently

remain in a developmental stage, the complexity of the ferroptotic process has made it clear that the successful deployment
of ferroptosis-inducing agents will ultimately require an understanding of how multiple parameters interact to dictate ferroptosis
sensitivity or resistance in individual tumors.
In this work, we develop a dynamic multistate discrete model
of the pathways underlying the ferroptotic process in order to
achieve a systems-level understanding of cellular susceptibility to
ferroptosis. We show that the model behaves in a manner that is
consistent with experimental observations. The model has allowed
us to explore global properties of ferroptosis susceptibility. Importantly, we show that a cell’s sensitivity to ferroptotic inducers
is a product of several interacting pathways, including PUFA-CoA
synthesis and incorporation into phospholipids, and the balance
between pro- and anti-oxidant species.
More broadly, we show how different combinations of input
variables (ACSL4, SCD1, Fptn, TFRC, and p53) alter ferroptosis sensitivity and obtain conclusions regarding the molecular proﬁles of
these agents that can promote or inhibit sensitivity to ferroptosis
induction (Figs. 4–8). For example, high ACSL4 and low SCD1
are necessary, but not suﬃcient, in our model to promote high
ferroptosis sensitivity (Fig. 5). Conversely, a combination of parameters that minimizes production of LOOH - the ﬁrst step in the
lipid peroxidation pathway, will desensitize the cell to ferroptosis
agents. As can be observed in Fig. 6, there are many combinations
of input variables that will lead to this result, indicating that
ferroptosis sensitivity is a systems-level process, and thus that
predicting ferroptosis sensitivity may ultimately require a geneor protein- signature approach in a patient setting. To this end,
we use the model framework and simulation results to derive a
cellular algorithm for ferroptosis sensitivity given known values of
input parameters (Fig. 7).
By simultaneously modeling the expression of multiple genes,
our model was able to expand and clarify observations in the
literature. ACSL4 has previously been shown to enhance sensitivity
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Fig. 8. Modeling ferroptosis sensitivity in FT-t cells. Ovarian cancer stem cell line FT-t has low p53, high TFRC, and low Fptn. We consider the sensitivity of FT-t cells to
erastin under varying SCD and ACSL4. The relationship between conditions experimentally tested and modeled is shown on the right-hand side. For example, the ﬁrst row
shows input conditions identical to the control FT-t row, except the input parameter SCD1 is set to low, which corresponds to a knock down of SCD1 in FT-t cells.

to ferroptosis inducers (Doll et al., 2017). Indeed, when simulating
ACSL4 knockdown, we observe that response to RSL3 is inhibited
(Fig. 3). Nevertheless, our systems-level approach predicted that
there exist conditions of SCD1 and other major players in the
ferroptotic cascade that render a cell unresponsive to ferroptotic
induction despite high levels of ACSL4 (Figs. 4–8).
We used an ovarian cancer stem cell model to test this prediction, since effective treatments for ovarian cancer remain limited,
and ferroptosis inducers may ultimately offer a therapeutic option
in this disease. The model we selected exhibits a gene expression
pattern that is generally concordant with that observed in ovarian
tumors. In particular, using conditions pertinent to FT-t ovarian
cancer stem cells (Yamamoto et al., 2016) (setting Fptn, TFRC,
and p53 to ‘low’, ‘high’, and ‘low’, respectively), the mathematical
model predicted that under conditions of high SCD1, ACSL4 would
be unable to exert this sensitizing effect (Fig. 8). This prediction
was validated experimentally (Fig. 9). These results are consistent with recent observations implicating SCD1 as an inhibitor
of ferroptosis (Tesfay et al., 2019), and the demonstration that
its products (MUFAs) promote ferroptosis resistance (Magtanong
et al., 2018); further, work from our laboratory has recently
shown that prolonged inhibition of SCD1 can trigger cell death
(Tesfay et al., 2019). Although this is somewhat surprising, given
the ability of cells to take up MUFAs from exogenous sources
(Kamphorst et al., 2013), a number of papers have similarly
demonstrated that sustained inhibition of SCD1 induces cell death
(Li et al., 2018; Leung and Kim, 2013; Mason et al., 2012; MinvilleWalz et al., 2010; Hess et al., 2010). In the experiment shown
in Fig. 9, we deliberately selected conditions under which the
effects of SCD1 inhibition were modest, in order to focus on the
combined inﬂuence of SCD1 and ACSL4 on the response of cells to
ferroptosis. This experimental strategy successfully illustrated the
interdependence of SCD1 and ACSL4 predicted by the model.
This example illustrates how intergenetic interactions can
affect biological response in ways that are not inherently intuitive,

and highlights the need for modeling to accurately capture the
multiple variables that ultimately dictate biological response. Interpreted in the context of patient response to therapy, our results
suggest that modeling approaches that incorporate the expression
of multiple genes will ultimately be required to successfully tailor
therapy to individual patients to realize “precision medicine”.
As our understanding of ferroptosis becomes more nuanced, it
will become increasingly essential to use modeling to predict the
combined contribution of multiple genes and pathways to ultimate
cellular response, and to expand the model both within the core
pathways of lipid peroxidation, and to additional pathways. Going
forward, our model can serve as a framework for the addition of
such new variables and pathways, which will ultimately improve
the precision with which ferroptosis sensitivity can be predicted.
For example, it has been suggested that iron concentration may
impact the activity of iron-binding proteins involved in ferroptosis
(e.g. ALOX15, SCD1) (Dixon and Stockwell, 2014; Konstorum et al.,
2018), which may represent an additional layer of iron-mediated
regulation of ferroptosis. Proteins that release or redistribute
iron intracellularly (Torti and Torti, 2013; Torti et al., 2018;
Chifman et al., 2014; Hower et al., 2009) may also impinge on
ferroptosis. For example, HO-1, an enzyme that degrades heme and
is induced as part of an antioxidant response mediated by Nrf2,
contributes to ferroptosis in several different contexts (Fang et al.,
2019; Hassannia et al., 2018; Kwon et al., 2015). Further, feedback
loops that redistribute intracellular iron, such as the release of
iron from degradation of ferritin in the authophagolysosome (Hou
et al., 2016; Sui et al., 2019), also impact the ferroptotic cascade.
Expansion or a focus of the model to intracellular iron distribution
could yield rich insights into the contribution of intracellular iron
distribution to ferroptosis. Additional contributors to ferroptosis
that may ultimately factor into the model include the MAP kinase
pathway, which plays a complex but as yet incompletely understood role in ferroptosis (Xie et al., 2016), as well as two recentlydescribed modulators of ferroptosis, AMPK (Lee et al., 2020)
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Fig. 9. FT-t cells were transfected with siRNA targeted to SCD1 (siSCD1), ACSL4 (siACSL4), non-targeting siRNA (siNTC) or siRNA targeted to both SCD1 and ACSL4
(siSCD1+siACSL4) for 48 h. a) Levels of SCD1 mRNA following knockdown of SCD1 and ACSL4 individually or together was Quantiﬁed by qRT-PCR. b) Levels of ACSL4 mRNA
following knockdown of SCD1 and ACSL4 individually or together was quantiﬁed by qRT-PCR. c) Cells were treated with 0.5 to 2 μM RSL3 in the presence or absence of
2 μM ferrostatin-1 for 24 h to assess sensitivity to ferroptosis. Cell viability was measured using calcein-AM. ∗ ∗ p<3.6E-29 (siNTC vs siSCD1 and siSCD1 vs siSCD1 + siACSL4)
d) Cell death was determined using Trypan-blue exclusion. UNT, untreated controls. ∗ p<2.4E-02 (siNTC vs siSCD1 and siSCD1 vs siSCD1+siACSL4). Represented are means
and standard deviations of three independent experiments, each performed using eight technical replicates per point.

and FSP1 (Doll et al., 2019; Bersuker et al., 2019). Finally, a
more in-depth modeling study of the complex contribution of
p53 to ferroptosis may help to resolve potentially conﬂicting
experimental results, which have demonstrated both pro- and
anti-ferroptotic effects of p53 (for examples, see (Magtanong et
al., 2018; Jiang et al., 2015; Xie et al., 2017)). Our model indicates
that low/medium levels of p53 are necessary, but not suﬃcient,
to induce ferroptosis, suggesting that other factors may impinge
on p53 to drive ﬁnal cellular outcome. A detailed, kinetic study
of wildtype as well as mutant p53 and their effects in different
cellular contexts may be required to clarify the full range of roles
that p53 can play in ferroptosis. Nevertheless, at present our
model contains suﬃcient critical players and interactions to shed
light on the processes regulating lipid peroxidation mechanisms
leading to ferroptosis. If properly adjusted to cell line or patient
data, the model could be used in the future to predict sensitivity
to pro-ferroptotic therapy and/or to optimize combinatorial effects
of ferroptotic agents with other anti-cancer agents.

4. Methods
4.1. A stochastic multistate discrete modeling framework
The mathematical model consists of ﬁve external inputs: ACSL4,
SCD1, ferroportin (Fptn), TFRC, and p53 and eleven variables (MUFA,
PUFAc, LPCAT3, LHP, ALOX15, ROS, SLC7A11, GPX4, LOOH, LOr, LIP),
where PUFAc represents PUFA-CoA, LHP represents LH-P, and LOr
represents the radical LO• . We represent the system with a state
vector at discrete time t as

x(t ) = (x1 (t ), x2 (t ), . . . , x10 (t ), x11 (t ) )
= (MU F A(t ), PU F Ac (t ), . . . , LOOH (t ), LOr (t )),
where xI ∈ {0, 1, 2} for all xi ∈ x. At each time step, the state
vector is updated as follows,

x(t + 1 ) = G(x(t ) ) = (gi (x(t ) ), pi ),
where gi (x(t ) ) = c (xi (t ), fi (x(t ∗ ) ).
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Fig. 10. Transition tables for each modeled species in the multistate rule speciﬁcation model of ferroptosis.

For each variable xi , a transition table, fi , is speciﬁed (Fig. 10).
The transition table takes as input all variables that act on xi , and
outputs a corresponding value of xi for the next time step. We
take x(t∗ ) to represent a state of the system x such that a subset
of xi ∈ x may have been updated. Then, gi imposes a continuity
constraint, c, on the output fi (x(t∗ )) which limits the jump size to
one level for each xi . The probability P that xi (t + 1 ) will update
using gi is



P (x(t + 1 ) ) =

gi (x(t ) )
xi (t )

is pi
is 1 − pi .

For all i, we take pi = 0.5. An asynchronous update scheme
is used at each time step, hence each variable is updated in a
random order. The steady states of the system do not depend on
the stochastic, continuous, or asynchronous update scheme in this
framework (Murrugarra et al., 2012).
System behavior was simulated using Matlab R2017A. Choice of
initial conditions of variables (aside from input variables, which are
explored in Section 2.2.2) within a physiological range did not impact the steady states. Further details on the choice of initial conditions can be found in the Supplementary Information.

4.2. Transition tables
The transition tables for the multistate rule-speciﬁcation model
for ferroptosis are in Fig. 10. We shall now motivate each entry.

4.2.1. Monounsaturated fatty acids (MUFA)
Production of the most abundant MUFAs in mammalian cells,
oleic and palmitoleic acid, depends on desaturation of the saturated fatty acids (SFAs) stearic acid and palmitic acid, respectively,
catalyzed by stearoyl-CoA desaturase (SCD1) (Paton and Ntambi,
2009). In cancer cells, SCD1 is the main regulator of MUFA levels (Igal, 2011). Nevertheless, MUFAs can also be imported into
cells directly, which can be modeled by increasing MUFA levels
independently of SFA levels and SCD1 activity.
We assume that availability of SFAs is much greater than of
MUFAs (Harayama et al., 2014), and thus when SFAs are converted
to MUFAs, qualitatively, SFA levels are not lowered in a proportional manner.
4.2.2. Acetylated polyunsaturated fatty acids (PUFA-CoA)
Membrane polyunsaturated fatty acids (PUFAs) are direct targets for the ferroptotic cascade via their peroxidation (Skouta et al.,
2014; Yang et al., 2016). In order for free fatty acids to be incorporated into phospholipid membranes, they must be converted to
acyl-CoA moieties by acyl-CoA synthetases. ACSL4 is an acyl-CoA
synthetase with a strong preference for arachidonic acid and other
PUFAs (Kagan et al., 2017; Doll et al., 2017), and its activity has
been found to be critical for sensitivity to ferroptosis inducers
(Doll et al., 2017; Dixon et al., 2015). We model the effect of ACSL4
as follows: at moderate levels of AA, moderate and high ACSL4
result in moderate PUFA abundance, whereas at high AA, PUFA
levels are directly related to ACSL4 levels.
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4.2.3. LPCAT3
Lysophosphatidylcholine Acyltransferase 3 (LPCAT3) is involved
in the glycerophospholipid remodeling pathway (Lands’ cycle)
which allows for the fatty acid composition of phospholipids to
be altered. LPCAT3 shows highest acyltransferase activity toward
PUFAs (Shindou et al., 2009). Accordingly, it has been shown that
LPCAT3 is essential for ferroptosis induced by inhibition of GPX4
(Dixon et al., 2015). It has been observed that in SCD1 knock-down
conditions, when MUFA levels are reduced, LPCAT3 levels are
increased (Ariyama et al., 2010). We thus model MUFAs as capable
of partially inhibiting LPCAT3.
4.2.4. PUFA-containing phospholipids (LH-P)
Polyunsaturated fatty acids (PUFAs) are incorporated into phospholipids either during de novo biosynthesis (the Kennedy pathway) or maturation and remodeling (the Lands cycle). The acyltransferase LPCAT3 preferentially adds PUFAs to phospholipids via
the Lands cycle (Shindou et al., 2009; Shindou and Shimizu, 2009;
Hishikawa et al., 2008), and is critical for ferroptosis sensitivity,
as discussed above. MUFAs can also inhibit PUFA incorporation
into phospholipids via LPCAT3-independent mechanisms: Ariyama
et al. (Ariyama et al., 2010) showed that knockdown of SCD1
(which would decrease MUFA levels) and LPCAT3 still resulted in
an increase in phospholipid PUFA levels over control in HeLa cells.
4.2.5. ALOX15
ALOX15 is a non-heme iron-binding lipid peroxidating enzyme.
It participates in reactions that lead to generation of lipid hydroperoxides (LOOH) from unsaturated lipids (LH) (this activity is
termed its lipoxygenase activity), as well as generation of peroxyl
radicals (LO• ) (among others) from lipid hydroperoxides (termed
its lipohydroperoxidase activity) (Ivanov et al., 2015; Girotti, 1998).
The presence of ALOX15 has been found to be critical for ferroptosis
sensitivity (Dixon et al., 2015; Shintoku et al., 2017), and it has recently been shown that p53 can modulate ferroptotic response by
increasing ALOX15 expression via the upregulation of SAT1, which is
proposed to act as a positive regulator of ALOX15 (Ou et al., 2016).
4.2.6. LIP
While intracellular iron regulation involves complex pathways
of transcriptional and post-translational modiﬁcations (Torti and
Torti, 2013), we consider a simple iron regulation model here,
which only involves the iron import protein transferrin receptor
1 (TFRC) and export protein ferroportin, both which are found in
the cellular plasma membrane. Loosely bound intracellular iron,
termed the labile iron pool (LIP) will occur with high TFRC and
low ferroportin, and minimal LIP will occur in the complementary
conditions. Attesting to the importance of these pathways in the
pathophysiology of iron regulation, alterations in levels of these
proteins are suﬃcient to affect tumor growth in animal models
(Basuli et al., 2017; Pinnix et al., 2010) and to predict survival of
cancer patients (Basuli et al., 2017). Other regulators of LIP, such
as the intracellular iron binding protein ferritin, or ferroportin
inhibitor hepcidin, can be added to the model if considered important with respect to iron-mediated ferroptosis sensitivity of the
cell.
4.2.7. ROS
The ability of iron to mediate production of hydroxyl free radicals via the Fenton reaction, which can then trigger peroxidation of
LH-P to LOOH and LOOH to LO• implicates the labile iron pool as
an important contributor to the reactive oxygen species (ROSs) that
participate in formation of lipid peroxides. Further, LO• can trigger
further free-radical mediated lipid peroxidation (Girotti, 1998). It
has been demonstrated that the iron chelator deferoxamine (DFO)
can inhibit ferroptosis (Dixon et al., 2012), while the strength of

the feedback of LO• on the peroxidation process and sensitivity to
ferroptosis has not yet been investigated. While iron can play a role
in ferroptosis that is independent of its free-radical activity (Dixon
and Stockwell, 2014), its contribution to the cellular ROS that is
involved in lipid peroxidation is currently considered a signiﬁcant
contributor to ferroptosis sensitivity (Stockwell et al., 2017), and
thus its effect on boosting ROS in the model is considered to be
stronger than that of LO• .
4.2.8. SLC7A11
SLC7A11 is a component of the cystine/glutamate antiporter
system xc − , and is the target of the pro-ferroptotic drug erastin
(Dixon et al., 2012). Additionally, the tumor suppressor p53
has been shown to be a transcriptional regulator of SLC7A11
(Jiang et al., 2015). Therefore, we model erastin as an inhibitor of
SLC7A11 independent of p53 activity, and p53 as a partial activator
of SLC7A11 via transcriptional modulation.
4.2.9. GPX4
Glutathione peroxidase 4 (GPX4) is a lipid hydroperoxide
reducer within biological membranes, and interference with its
activity will promote ferroptosis: indeed, RSL3 acts as a ferroptosis
inducer by direct inhibition of GPX4 (Yang et al., 2014). GPX4
requires GSH for its reducing activity, which in turn requires
cystine, thereby explaining how erastin can initiate ferroptosis:
by inhibiting cystine uptake via SLC7A11, it limits production of
GSH and therefore the substrate for GPX4 activity (Stockwell et al.,
2017; Yang and Stockwell, 2016). We model GPX4 activity to be
inhibited by RSL3, independent of SLC7A11 activity, and in absence
of RSL3, its activity is set proportional to SLC7A11.
4.2.10. LOOH and LO•
Lipid hydroperoxides (LOOH) and lipid radicals (LO• ) are lipid
peroxidation products that can be produced by ROS (Girotti, 1998)
and lipoxygenases (e.g. ALOX15) (Ivanov et al., 2015) in a fashion
independent of each others’ activity (Feng and Stockwell, 2018).
The anti-oxidant activity of GPX4 is at the level of LOOH, which
can be converted to LOH in the presence of GPX4 (Girotti, 1998).
We thus model the generation of LOOH as a function of ROS and
ALOX15 activity on the substrate LH-P. Generation of LO• is modeled in a similar fashion, where the substrate is now LOOH and
GPX4 can mitigate the pro-oxidant effect of ROS and ALOX15. We
consider each of these reactions to occur on a fraction of available
substrate – therefore generation of LOOH does not deplete LH-P
in a 1–1 fashion, but may be limited by limited availability of
LH-P (and a similar consideration holds for generation of LO• ).
Since the presence of lipid radicals is considered to be the initiator of ferroptotic processes (Stockwell et al., 2017; Yang and
Stockwell, 2016; Yang et al., 2016), we consider LO• as a proxy for
ferroptosis in our model.
4.2.11. Auxiliary functions: additive(x,y) and not(x)
The additive(x,y) function represents the symmetric, additive effect of two variables (x,y) on a variable z, and can be represented
with the following algorithm:

z = additive(x, y ){
sumxy = x + y
if sumxy ≥ 3 : z = 2
else if sumxy == 2 : z = 1
else : z = 0}
The second auxiliary function, not(x), represents the action of
an inhibitor x on y.
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4.3. In vitro experimental system
Cell culture. FT, FT-i and FT-t cells (described in (Basuli et al.,
2017; Yamamoto et al., 2016)) were cultured in DMEM (Gibco)
containing 10% FBS (Gemini Bio-Products). Cells were passaged
less than ﬁve times before use for experiments. All cells were
maintained at 37°C in a humidiﬁed incubator at 5% CO2 .
Real-time qRTPCR. 200 ng of RNA was reverse transcribed in a
total volume of 50 μl using a reverse transcription reagents kit
(Applied Biosystems). To make a standard curve, serial dilutions of
RNA from one sample were added to the RT reaction. Aliquots (2
μl) of cDNA were added to a 18 μl reaction mixture containing
10 μl of 2× SYBR® Green PCR Master Mix (BioRad) and 400 nm
primers. Absence of DNA contamination was conﬁrmed by performing PCR from cDNA without reverse transcriptase. Primers
used were:
-

human
human
human
human
human
human

SCD1 forward: AAACCTGGCTTGCTGATG
SCD1 reverse: GGGGGCTAATGTTCTTGTCA
ACSL4 forward: CATCCCTGGAGCAGATACTCT
ACSL4 reverse: TCACTTAGGATTTCCCTGGTCC
β -Actin forward: TTG CCG ACA GGA TGC AGA AGG A
β -Actin reverse: AGG TGG ACA GCG AGG CCA GGA T

Cell viability. 50 0 0 FT-t cells were transfected with siRNA for
48 h. Afterwards, cells were treated with 0.5 μM of RSL3 (Selleckchem) in presence or absence of 2 μM ferrostatin-1 (Selleckchem) for 24 h. Cell viability was assessed using calcein-AM
(Millipore), a ﬂuorescent dye that stains living cells. Brieﬂy, cells
plated in 96 well black-walled plates (Corning) were incubated
with 2 uM calcein-AM for 30 min at 37°C in a humidiﬁed incubator at 5% CO2 . Fluorescence was measured in a ﬂuorescent plate
reader (BioTek, Synergy2) using 480/520 nm excitation/emission
(Stoddart, 2011).
Trypan-blue exclusion assay. 1 × 106 FT-t cells were transfected
with siRNA for 48 h. Afterwards, cells were treated with 0.5 to
2 μM of RSL3 (Selleckchem) for 24 hrs. Cells were counted following staining with 0.4% Trypan-blue (Invitrogen), a dye that stains
dead cells but is excluded by living cells. The percentage of stained
cells as a fraction of the total number of cells was quantiﬁed using
a hemocytometer (Stoddart, 2011).
siRNA knock-down experiments. All reagents were obtained from
GE Dharmacon (Lafayette, CO, USA). 12 ng of ON-TARGETplus Human SCD1 siRNA (L-0 05,061–0 0–0 010), ON-TARGETplus Human
ACSL4 (2182) siRNA (L-0 09,364–0 0–0 0 05) and siNTC (cat#: d001,810–10–05) were used for knockdown experiments. Transfections were performed according to the manufacturer’s recommendations using Dharmafect #1 transfection reagent (cat: T-2001).
Knockdown eﬃciencies were conﬁrmed at the time of harvest by
RT-qPCR.
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